SP Scientific launches new, powerful lyophilizer control system

SP Scientific announces the launch of LyoS 2.0 – a line-of-sight enabled lyophilizer control system able to control platforms from development to production units, making cycle transfer and scale-up that much simpler.

LyoS logo.

Image credit: SP Scientific

Building upon over 50 years of freeze-drying experience, the LyoS 2.0 control system delivers unmatched process control for all stages of the cycle, from freezing to primary and secondary drying.  User definable process alarms protect your valuable product and automated system tests to ensure your lyophilizer is running optimally.  All of this in a software package that is easy to use and visualize your data.

The LyoS 2.0 control system is designed to control proprietary SP freeze drying technologies including ControLyo® ice nucleation, SMART automatic cycle development and LyoFlux® TDLAS continuous process monitoring.

Optional 21 CFR Part 11 compliance capabilities ensure that LyoS 2.0 control system software is both fully configurable and fully validatable for regulated pharmaceutical and biotechnology applications. SP Scientific offers testing protocols intended to support the processes that will be performed by the purchaser and/or end user, as well as onsite control system IQ/OQ validation support and comprehensive factory-initiated software validation.

Designed for SP's research, development, and production lyophilizers, including the LyoCapsule, LyoStar, Genesis, Ultra and LyoConstellation.  LyoS 2.0 and SP Line of Sight technologies can be upgraded on to certain other freeze dryers.  

For further information on the LyoS 2.0 lyophilizer control system please contact SP Scientific on +1-845-255-5000 (+44-1473-240000 in Europe).

Line of Sight is a breakthrough concept from SP Scientific comprising a suite of freeze-drying equipment with scalable lyophilization technologies and process analytical tools (PAT). ​Line of Sight has been designed for pharmaceutical developers and manufacturers to assist them to achieve drug commercialization objectives.

Line of Sight technologies have been developed to provide the tools for a more successful scale-up of a lyophilization process from formulation through to full commercial production.

This ensures superior product quality and uniformity and creates a data-rich environment across all sizes of freeze-drying systems. The next step forward in Lyophilization, the science of freeze drying, is being developed for pharmaceutical applications by use of enhanced technological capabilities, improved process and product understanding, and by implementing Line of Sight enabled freeze drying equipment.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    SP Scientific Products. (2020, May 13). SP Scientific launches new, powerful lyophilizer control system. News-Medical. Retrieved on May 25, 2022 from https://www.news-medical.net/news/20190111/SP-Scientific-launches-new-powerful-lyophilizer-control-system.aspx.

  • MLA

    SP Scientific Products. "SP Scientific launches new, powerful lyophilizer control system". News-Medical. 25 May 2022. <https://www.news-medical.net/news/20190111/SP-Scientific-launches-new-powerful-lyophilizer-control-system.aspx>.

  • Chicago

    SP Scientific Products. "SP Scientific launches new, powerful lyophilizer control system". News-Medical. https://www.news-medical.net/news/20190111/SP-Scientific-launches-new-powerful-lyophilizer-control-system.aspx. (accessed May 25, 2022).

  • Harvard

    SP Scientific Products. 2020. SP Scientific launches new, powerful lyophilizer control system. News-Medical, viewed 25 May 2022, https://www.news-medical.net/news/20190111/SP-Scientific-launches-new-powerful-lyophilizer-control-system.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
SP launches SP Hull LyoStar® 4.0 R&D freeze dryer to enhance speed to market in drug development